Home Environment as a Source of Life-Threatening Azole-Resistant Aspergillus fumigatus in Immunocompromised Patients.
A case of fatal aspergillosis due to a TR46/Y121F/T289A azole-resistant Aspergillus fumigatus is reported. Environmental investigations at the patient's residence led to the recovery of TR46/Y121F/T289A isolates, genotypically indistinguishable from the clinical isolate, supporting for the first time the direct role of household as potential source of azole-resistant invasive aspergillosis.
Parasitology and Medical Mycology Laboratory, Nantes University Hospital.|Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2.
Rose-Anne
RA
Lavergne
Parasitology and Medical Mycology Laboratory, Amiens University Hospital.|EA 4666, CAP-Santé (FED 4231).
Taieb
T
Chouaki
Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital.
Ferry
F
Hagen
Department of Pneumology.
Bénédicte
B
Toublanc
INSERM U1088, Jules Verne University of Picardy.|Intensive Care Unit, Amiens University Hospital, France.
Hervé
H
Dupont
Department of Pneumology.
Vincent
V
Jounieaux
Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital.|Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlands.
Jacques F
JF
Meis
Parasitology and Medical Mycology Laboratory, Nantes University Hospital.|Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2.
Florent
F
Morio
Parasitology and Medical Mycology Laboratory, Nantes University Hospital.|Parasitology and Medical Mycology Department, Nantes University, Nantes Atlantique Universities, EA1155-IICiMed, Institut de Recherche en Santé 2.
Patrice
P
Le Pape
D000368:Aged; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology*; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000235:genetics; D001393:Azoles / Q000494:pharmacology / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D025141:Drug Resistance, Fungal; D017809:Fatal Outcome; D005656:Fungal Proteins / Q000235:genetics; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab / Q000009:adverse effects / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009154:Mutation
D000935:Antifungal Agents; D001393:Azoles; D005656:Fungal Proteins; D003577:Cytochrome P-450 Enzyme System; D000069285:Infliximab; C465526:cytochrome P-450 CYP51A, Aspergillus
Aspergillus fumigatus; TR46/Y121F/T289A; azole resistance; environment; invasive aspergillosis